LEXX
Lexaria Bioscience·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LEXX
Lexaria Bioscience Corp.
A global innovator in drug delivery platforms
Pharmaceutical
12/09/2004
01/12/2021
NASDAQ Stock Exchange
7
08-31
Common stock
#100 – 740 McCurdy Road
Kelowna
BC Canada V1X 2P7
--
Lexaria Bioscience Corp. was incorporated on December 9, 2004 pursuant to the laws of the State of Nevada. The company is a biotechnology company that utilizes the patented DehydraTECHTM drug delivery technology to develop enhanced bioavailability of a wide range of fat-soluble active molecules and active pharmaceutical ingredients. DehydraTECH combines lipophilic molecules or APIs with specific long-chain fatty acids and carrier compounds, thereby improving the way they enter the bloodstream, increasing their effectiveness and allowing lower overall doses, while promoting healthier oral intake methods. The company's technology can be applied to a variety of therapeutic indications, including hypertension and heart disease, diabetes, etc.
Company Financials
EPS
LEXX has released its 2025 Q2 earnings. EPS was reported at -0.15, versus the expected -0.17, beating expectations. The chart below visualizes how LEXX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LEXX has released its 2025 Q4 earnings report, with revenue of 174.00K, reflecting a YoY change of 107.14%, and net profit of -2.70M, showing a YoY change of -23.35%. The Sankey diagram below clearly presents LEXX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
